ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 794

Color Doppler Ultrasonography Findings in Giant Cell Arteritis and Their Relationship with Clinical Manifestations

Cristina Ponte1,2, Ruth Geraldes3, Anthea Craven1, Andrew Judge4, Peter C. Grayson5, Ravi Suppiah6, Joanna Robson1, Richard A. Watts7, Peter A. Merkel8 and Raashid Luqmani1, 1Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 2Rheumatology and Metabolic Bone Diseases Department, Rheumatology Research Unit - IMM, Lisbon Academic Medical Centre, Lisbon, Portugal, 3Neurology Department, Lisbon Academic Medical Centre, Lisbon, Portugal, 4Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, 5NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, 6Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 7Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, 8University of Pennsylvania, Philadelphia, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Diagnostic imaging, giant cell arteritis, Temporal arteritis, ultrasound and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Colour Doppler ultrasonography (CDU) of the temporal (TA), axillary (AA) and common carotid arteries (CA) has excellent sensitivity and specificity for the diagnosis of GCA, typically showing halos (dark areas around the arterial walls) and stenoses or occlusions. The CDU pattern of patients with extra cranial and cranial GCA has been reported to substantially differ; visual impairment and age are inversely correlated to extra cranial GCA. In addition, involvement of the vertebral arteries (VA) is associated with vertebrobasilar stroke. The aim of this analysis was to evaluate the type and frequency of CDU abnormalities in the TA, AA, CA and VA and their relationship with clinical features amongst patients with a submitted diagnosis of GCA in the DCVAS study (a multinational observational study to develop diagnostic criteria and update classification criteria for primary vasculitis, using data from patients with vasculitis and comparators).

Methods

This analysis included data from all patients recruited into DCVAS through April 2014 who had complete 6 month follow-up data, a submitted diagnosis of GCA, and whose tests included a CDU of TA, AA, CA or VA. The presence of halo was considered diagnostic of GCA. Patients were defined as having cranial GCA if they underwent CDU of at least TA and AA but only had abnormities in TA; patients with extra-cranial GCA had involvement of the proximal arm arteries. CDU findings of each artery and cranial/extra cranial pattern were compared to clinical features using Chi-square or Mann-Whitney tests.

Results

GCA was diagnosed in 431 patients; 336 underwent TA biopsy (78%) and 133 (31%) underwent CDU of the following arterial territories: 107 TA, 72 CA, 42 AA and 21 VA. In 8 cases all 4 areas were evaluated; in 27 cases 3 areas; in 31 cases 2 areas; and in 67 cases 1 area. Halo occurred in 75% (TA), 16% (CA), 34% (AA), 41% (VA) of cases; stenosis was seen in 31% (TA), 11% (CA), 16% (AA) and 41% (VA); occlusion was present in 11% (TA), 0% (CA), 3% (AA) and 6% (VA); CDU was normal in 16% (TA), 73% (CA), 58% (AA) and 39% (VA). Table 1 shows that older people were more prone to having a positive TA CDU; headache was less frequent in extra-cranial GCA; PMR occurred in a higher number of patients with CA involvement; and an association between vascular examination and CDU was only found in AA (p<0.05). Moreover, no type of CDU involvement correlated to eye symptoms.

Conclusion

Despite the high sensitivity of CDU and its ability to evaluate several vessels, clinicians usually use TA biopsy for the diagnosis of GCA. Extra-cranial involvement is frequent in GCA and inversely correlated to history of headache. The presence of abnormal CDU findings in several arterial territories supports the use of more extensive imaging in GCA. No significant correlation between cranial GCA and eye symptoms was found, but the low number of patients with extra cranial CDU was a limitation in the analysis.

Table 1: Relationship between the CDU findings and clinical features.

CDU findings (n)

Female sex

n (%)

Mean age

(±SD)

Eye Sympt. 1

n (%)

PMR

n (%)

Jaw claudic.

n (%)

Headache

n (%)

Stroke / TIA

n (%)

Mean ESR

(±SD)

TAB positive 2

n (%)

Vasc. examination

abnormality 3 n (%)

TA + (70 patients)

40 (57%)

74±9

29 (41%)

16 (23%)

25 (36%)

49 (70%)

3 (4%)

73±31

45 (83%)

39 (59%)

TA –  (15 patients)

12 (80%)

70±7

5 (33%)

5 (33%)

4 (27%)

12 (80%)

1 (7%)

66±31

6 (60%)

8 (53%)

p value

0.09

0.03

0.56

0.39

 0.50

0.44

0.69

0.35

0.09

0.68

VA + (7 patients)

4 (57%)

78±5

5 (71%)

0 (0%)

3 (43%)

6 (86%)

1 (14%)

83±15

7 (100%)

–

VA –  (7 patients)

4 (57%)

70±7

2 (29%)

2 (29%)

2 (29%)

7 (100%)

0 (0%)

88±43

3 (50%)

–

p value

 1.00

0.03

0.11

0.13

0.58

0.30

0.30

0.39

0.03

–

CA + (10 patients)

7 (70%)

72±8

3 (30%)

5 (50%)

1 (10%)

1 (10%)

0 (0%)

77±17

3 (100%)

0 (0%)

CA –  (45 patients)

31 (69%)

73±8

22 (49%)

7 (16%)

11 (24%)

32 (71%)

2 (4%)

71±30

27 (79%)

3 (8%)

p value

0.95 

 0.81

0.28

0.02

0.32

0.001

0.50

 0.59

0.38

0.37

AA + (13 patients)

11 (85%)

73±8

6 (46%)

1 (8%)

4 (31%)

7 (54%)

0 (0%)

70±26

7 (78%)

5 (50%)

AA –  (22 patients)

13 (59%)

74±5

6 (27%)

2 (9%)

6 (27%)

15 (68%)

1 (5%)

79±30

15 (75%)

0 (0%)

p value

 0.15

 0.59

0.26

0.87

0.83

0.40

0.44

 0.29

0.87

0.002

Cranial GCA

(19 patients)

13 (68%)

74±8

5 (26%)

2 (11%)

5 (26%)

15 (79%)

1 (5%)

76±31

13 (77%)

–

Extra cranial GCA

(17 patients)

15 (88%)

74±6

8 (47%)

3 (18%)

5 (29%)

8 (47%)

0 (0%)

74±24

8 (73%)

–

p value

 0.15

 0.79

0.20

0.54

0.84

0.04

0.34

 0.94

0.63

(+) Positive findings for GCA; (-) Negative findings for GCA;  AA – Axillary artery; CA – Carotid artery; CDU – Colour Doppler ultrasonography, ESR – Erythrocyte Sedimentation Rate; GCA – Giant Cell Arteritis; PMR – Polymyalgia Rheumatica; SD – Standard deviation; TA – Temporal artery; TAB – Temporal artery biopsy; TIA – Transient Ischaemic Attack; VA – Vertebral artery.

1 Eye symptoms were considered when “amaurosis fugax”, “sudden visual loss”, “blurred vision in either eye”, “diplopia” or “optic neuritis” was recorded.

2 TAB was defined has positive when “definitive vasculitis” or “consistent with vasculitis but not definitive” was recorded.

3 The presence of a diminished/absent pulse, tenderness, hard ‘cord like’ or/and bruit in the area scanned.


Disclosure:

C. Ponte,
None;

R. Geraldes,
None;

A. Craven,
None;

A. Judge,
None;

P. C. Grayson,
None;

R. Suppiah,
None;

J. Robson,
None;

R. A. Watts,
None;

P. A. Merkel,

Genentech and Biogen IDEC Inc.,

2,

Bristol-Myers Squibb,

2,

GlaxoSmithKline,

2,

Actelion Pharmaceuticals US,

2,

Actelion Pharmaceuticals US,

5,

Sanofi-Aventis Pharmaceutical,

5,

Chemocentryx,

5;

R. Luqmani,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/color-doppler-ultrasonography-findings-in-giant-cell-arteritis-and-their-relationship-with-clinical-manifestations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology